Literature DB >> 12429735

Syntrophin gamma 2 regulates SCN5A gating by a PDZ domain-mediated interaction.

Yijun Ou1, Peter Strege, Steven M Miller, Jonathan Makielski, Michael Ackerman, Simon J Gibbons, Gianrico Farrugia.   

Abstract

SCN5A encodes the alpha subunit of the cardiac muscle and intestinal smooth muscle mechanosensitive Na(+) channel. Mechanosensitivity in the intestine requires an intact cytoskeleton. We report, using laser capture microdissection, single cell PCR, and immunohistochemistry, that syntrophins, scaffolding proteins, were expressed in human intestinal smooth muscle cells. The distribution of syntrophin gamma 2 was similar to that of SCN5A. Yeast two-hybrid and glutathione S-transferase pull-down experiments show that SCN5A and syntrophin gamma 2 co-express and that the PDZ domain of syntrophin gamma 2 directly interacts with the C terminus of SCN5A. In native cells, disruption of the C terminus-syntrophin gamma 2 PDZ domain interaction using peptides directed against either region result in loss of mechanosensitivity. Co-transfection of syntrophin gamma 2 with SCN5A in HEK293 cells markedly shifts the activation kinetics of SCN5A and reduces the availability of Na(+) current. We propose that syntrophin gamma 2 is an essential Na(+) channel-interacting protein required for the full expression of the Na(+) current and that the SCN5A-syntrophin gamma 2 interaction determines mechanosensitivity and current availability.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12429735     DOI: 10.1074/jbc.M209938200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  45 in total

1.  Human macrophage SCN5A activates an innate immune signaling pathway for antiviral host defense.

Authors:  Alexis Jones; Danielle Kainz; Faatima Khan; Cara Lee; Michael D Carrithers
Journal:  J Biol Chem       Date:  2014-11-03       Impact factor: 5.157

2.  Diseases caused by mutations in Nav1.5 interacting proteins.

Authors:  John W Kyle; Jonathan C Makielski
Journal:  Card Electrophysiol Clin       Date:  2014-12-01

3.  Quantification of gastrointestinal sodium channelopathy.

Authors:  Yong Cheng Poh; Arthur Beyder; Peter R Strege; Gianrico Farrugia; Martin L Buist
Journal:  J Theor Biol       Date:  2011-09-21       Impact factor: 2.691

4.  Targeting ion channels for the treatment of gastrointestinal motility disorders.

Authors:  Arthur Beyder; Gianrico Farrugia
Journal:  Therap Adv Gastroenterol       Date:  2012-01       Impact factor: 4.409

5.  Structure of the split PH domain and distinct lipid-binding properties of the PH-PDZ supramodule of alpha-syntrophin.

Authors:  Jing Yan; Wenyu Wen; Weiguang Xu; Jia-Fu Long; Marvin E Adams; Stanley C Froehner; Mingjie Zhang
Journal:  EMBO J       Date:  2005-10-27       Impact factor: 11.598

6.  Nav channel mechanosensitivity: activation and inactivation accelerate reversibly with stretch.

Authors:  Catherine E Morris; Peter F Juranka
Journal:  Biophys J       Date:  2007-05-11       Impact factor: 4.033

Review 7.  A novel mechanism for the treatment of angina, arrhythmias, and diastolic dysfunction: inhibition of late I(Na) using ranolazine.

Authors:  Lars S Maier
Journal:  J Cardiovasc Pharmacol       Date:  2009-10       Impact factor: 3.105

8.  Mechanosensitivity of Nav1.5, a voltage-sensitive sodium channel.

Authors:  Arthur Beyder; James L Rae; Cheryl Bernard; Peter R Strege; Frederick Sachs; Gianrico Farrugia
Journal:  J Physiol       Date:  2010-11-01       Impact factor: 5.182

9.  Cytoskeletal basis of ion channel function in cardiac muscle.

Authors:  Matteo Vatta; Georgine Faulkner
Journal:  Future Cardiol       Date:  2006-07

10.  Sodium channel mutation in irritable bowel syndrome: evidence for an ion channelopathy.

Authors:  Yuri A Saito; Peter R Strege; David J Tester; G Richard Locke; Nicholas J Talley; Cheryl E Bernard; James L Rae; Jonathan C Makielski; Michael J Ackerman; Gianrico Farrugia
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-12-04       Impact factor: 4.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.